Latest News on MMSI

Financial News Based On Company


Advertisement
Advertisement

Merit Medical Systems chief legal officer sells $1.44 million in stock

https://www.investing.com/news/insider-trading-news/merit-medical-systems-chief-legal-officer-sells-144-million-in-stock-93CH-5033745
Brian G. Lloyd, Chief Legal Officer at Merit Medical Systems Inc. (NASDAQ:MMSI), sold 16,722 shares totaling $1.44 million on November 16, 2026, after acquiring them through stock options. The sale was executed via a Rule 10b5-1 trading plan. Despite the sale, the stock is considered undervalued with a "GREAT" financial health score, and analysts have a positive outlook, raising price targets after a strong Q3 earnings report.

After exercising options at $37.71 per share, Brian G. Lloyd sold 16,722 Merit Medical (MMSI) shares.

https://www.stocktitan.net/sec-filings/MMSI/form-4-merit-medical-systems-inc-insider-trading-activity-9dee31c42c0b.html
Brian G. Lloyd, Chief Legal Officer and Secretary of Merit Medical Systems (MMSI), exercised options for 16,722 shares at $37.71 per share on November 16, 2026. He subsequently sold all 16,722 shares at a weighted-average price of $86.325 per share. These transactions were executed under a Rule 10b5-1 trading plan established on May 21, 2026.

Form 4 Merit Medical Systems Inc: Brian G. Lloyd (CHIEF LEGAL OFFICER, SECRETARY) For: 16 November

https://in.investing.com/news/stock-market-news/form-4-merit-medical-systems-inc-brian-g-lloyd-chief-legal-officer-secretary-for-16-november-93CH-5710561
This article reports on a Form 4 filing for Merit Medical Systems Inc, detailing an insider transaction by Brian G. Lloyd, who serves as Chief Legal Officer and Secretary. The filing pertains to activity on November 16. The content is brief, primarily serving as an announcement of the filing.

Merit Medical Systems chief legal officer sells $1.44 million in stock By Investing.com

https://in.investing.com/news/stock-market-news/merit-medical-systems-chief-legal-officer-sells-144-million-in-stock-93CH-5710558
Merit Medical Systems Inc.'s Chief Legal Officer, Brian G. Lloyd, sold 16,722 shares of common stock for $1.44 million after exercising non-qualified stock options. This sale occurred after the stock experienced a significant six-month rally and despite being considered undervalued by InvestingPro. The company recently reported strong Q3 earnings and raised its full-year guidance, leading to several analyst price target increases.

A 16,722-share sale is proposed by Merit Medical (MMSI) officer Brian Lloyd.

https://www.stocktitan.net/sec-filings/MMSI/144-merit-medical-systems-inc-sec-filing-f9fac35fc4f9.html
Merit Medical Systems, Inc. (MMSI) officer Brian Lloyd has proposed selling 16,722 common shares, valued at approximately $1.44 million, with an approximate sale date of November 16, 2026. The shares were acquired on the same date through a stock option exercise paid in cash. This transaction is governed by a Rule 10b5-1 plan adopted on May 21, 2026.
Advertisement

Winners and losers of Q3: Merit Medical Systems vs the rest of the healthcare equipment and supplies stocks

https://www.tradingview.com/news/stockstory:dffc59b1a094b:0-winners-and-losers-of-q3-merit-medical-systems-vs-the-rest-of-the-healthcare-equipment-and-supplies-stocks/
This article reviews the Q3 2026 earnings for healthcare equipment and supplies stocks, highlighting Merit Medical Systems (MMSI) as a strong performer despite a post-earnings stock dip due to high investor expectations. It also details the best performer, Lantheus (LNTH), and the weakest, Dentsply Sirona (XRAY), along with positive results from GE HealthCare (GEHC) and Haemonetics (HAE). The sector as a whole saw revenues beat estimates but stock prices collectively declined.

Freedom Capital Markets maintains Merit Medical Systems at Hold, keeps price target at $90

https://www.tradingview.com/news/tradingview:38192028cfc7a:0-freedom-capital-markets-maintains-merit-medical-systems-at-hold-keeps-price-target-at-90/
Freedom Capital Markets has reiterated its "Hold" rating for Merit Medical Systems (MMSI) and maintained a price target of $90, suggesting a 2.2% upside from its recent closing price. This follows several other analyst actions in the past month, with price targets ranging from $92 to $121.

Trading the Move, Not the Narrative: (MMSI) Edition

https://news.stocktradersdaily.com/news_release/151/Trading_the_Move,_Not_the_Narrative:_MMSI_Edition_111226012002_1794507602.html
This article provides a detailed analysis of Merit Medical Systems Inc. (NASDAQ: MMSI), outlining weak near and mid-term sentiment and a neutral long-term outlook. It presents three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop levels. The analysis also highlights a significant short setup with an exceptional risk-reward ratio.

Does WRAPSODY Registry Data Change The Bull Case For Merit Medical Systems Stock (MMSI)?

https://simplywall.st/stocks/us/healthcare/nasdaq-mmsi/merit-medical-systems/news/does-wrapsody-registry-data-change-the-bull-case-for-merit-m
Merit Medical Systems recently reported strong third-quarter 2026 sales and net income, slightly raising its full-year revenue guidance. The company highlighted new real-world WRAPSODY registry data that aligns with prior trial outcomes, providing long-term support for the device across multiple geographies. This updated evidence and guidance offer investors a clearer understanding of the WRAPSODY product suite's integration into Merit Medical Systems' broader portfolio of catheter-based therapies and single-use devices, reinforcing the investment narrative for MMSI.

Merit Medical presents real-world data from AVF cohort of WRAP Global registry

https://vascularnews.com/merit-medical-presents-real-world-data-from-avf-cohort-of-wrap-global-registry/
Merit Medical Systems has released real-world data from the arteriovenous fistula (AVF) cohort of its WRAP Global registry, evaluating the Wrapsody cell-impermeable endoprosthesis. The registry's six-month primary patency rates for the device align with findings from the WAVE pivotal trial, demonstrating favorable performance in patients experiencing stenosis or occlusion in vascular access. These results are expected to boost physician confidence and optimize patient care for the Wrapsody CIE, which has received regulatory approvals in the US, Canada, EU, and Brazil.
Advertisement

Merit Medical Systems, Inc. (MMSI) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/MMSI/seasonality/
The article provides a seasonal returns chart for Merit Medical Systems, Inc. (MMSI), showing the average monthly price return from 2016 to 2026. It also displays the stock's recent performance, closing at $87.23 with a -2.67% change on November 6. The content appears to be incomplete due to an error message, "Oops, something went wrong," but key financial data is still present.

Here's Why You Should Retain MMSI Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:8e0b135ea094b:0-here-s-why-you-should-retain-mmsi-stock-in-your-portfolio-for-now/
Merit Medical Systems, Inc. (MMSI) is positioned for growth due to its strong product portfolio, global expansion, and strategic acquisitions, despite challenges from China market pressures and gross margin headwinds. The company delivered an average earnings surprise of 13% over the past four quarters and projects 10.6% growth for the next five years. While product innovation and clinical evidence contribute to its expansion, competitive pressure and tariff-related costs remain concerns.

Merit Medical reports positive real-world data for dialysis device By Investing.com

https://in.investing.com/news/stock-market-news/merit-medical-reports-positive-realworld-data-for-dialysis-device-93CH-5684100
Merit Medical Systems, Inc. announced positive real-world data from its WRAPSODY Global registry for its WRAPSODY Cell-Impermeable Endoprosthesis, a device used in hemodialysis patients experiencing vascular access stenosis. The study showed 6-month primary patency rates of 92.7% for target lesions and 76.7% for access circuits, surpassing results from a prior pivotal trial. The device, which received U.S. FDA approval in December 2024, aims to restore functionality in arteriovenous fistulas for patients with advanced kidney disease.

Merit Medical reports real-world patency data for its Wrapsody device

https://www.streetinsider.com/Corporate+News/Merit+Medical+reports+real-world+patency+data+for+its+Wrapsody+device/27296749.html
Merit Medical Systems presented real-world clinical data from its WRAPSODY Global Registry, showing a six-month target lesion primary patency rate of 92.7% and an access circuit primary patency rate of 76.7% for its Wrapsody device. These results compare favorably to the WAVE pivotal trial data. The WRAPSODY device, designed for hemodialysis patients with vascular access issues, has received regulatory approvals in the U.S., Canada, Europe, and Brazil.

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

https://www.stocktitan.net/news/MMSI/merit-medical-presents-real-world-data-from-the-avf-cohort-of-the-ltevkwafrws3.html
Merit Medical Systems (MMSI) announced positive six-month results from the arteriovenous fistula (AVF) cohort of its WRAPSODY (WRAP) Global registry, involving 237 patients across 31 sites. The data showed a target lesion primary patency of 92.7% and an access circuit primary patency of 76.7%, both surpassing results from the WAVE pivotal trial. These real-world findings reinforce the favorable performance of the WRAPSODY Cell-Impermeable Endoprosthesis in maintaining vascular access for hemodialysis patients.
Advertisement

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

https://finance.yahoo.com/healthcare/articles/merit-medical-presents-real-world-142500073.html
Merit Medical Systems announced positive real-world data from the arteriovenous fistula (AVF) cohort of its WRAPSODY (WRAP) Global registry, showing high 6-month target lesion primary patency (92.7%) and access circuit primary patency (76.7%) for its Cell-Impermeable Endoprosthesis (CIE). These results surpass those from the WAVE pivotal trial, validating the device's favorable performance in routine clinical practice for hemodialysis patients. The WRAPSODY CIE aims to reduce the burden of repeated interventions by maintaining vascular access functionality.

Merit Medical Stock In Focus After Earnings Beat And Higher 2026 Guidance

https://simplywall.st/stocks/us/healthcare/nasdaq-mmsi/merit-medical-systems/news/merit-medical-stock-in-focus-after-earnings-beat-and-higher
Merit Medical Systems reported strong third-quarter 2026 sales and net income, alongside an increase in full-year 2026 revenue guidance. The company's investment narrative continues to focus on operational efficiency, a broad product range, and disciplined acquisitions to fill product gaps. While the higher guidance is incremental, it suggests that current operations are tracking well with internal plans, despite ongoing concerns about margins, tariffs, and reimbursement challenges.

Merit Medical Systems, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:MMSI) 2026-11-03

https://seekingalpha.com/article/4961820-merit-medical-systems-inc-2026-q3-results-earnings-call-presentation
Merit Medical Systems, Inc. (MMSI) has published its slide deck in conjunction with their 2026 Q3 earnings call, which took place on November 3, 2026, at 6:05 PM ET. The company reported Q3 EPS of $1.12, beating estimates by $0.08, and revenue of $416.24M, an 8.35% year-over-year increase, beating by $5.65M.

Merit Medical Systems Q3 revenue up 8.4% to USD 416.2M

https://medicalbuyer.co.in/merit-medical-systems-q3-revenue-up-8-4-to-usd-416-2m/
Merit Medical Systems announced robust financial results for Q3 2026, with revenue increasing 8.4% to $416.2 million, surpassing expectations. The growth was primarily driven by strong organic, constant currency revenue growth and better-than-expected demand across both Foundational and Therapeutic platforms. The company also raised its 2026 revenue and non-GAAP earnings per share guidance, reflecting its strong performance and confidence in executing its strategic plans.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Just Reported And Analysts Have Been Lifting Their Price Targets

https://simplywall.st/stocks/us/healthcare/nasdaq-mmsi/merit-medical-systems/news/merit-medical-systems-inc-nasdaqmmsi-just-reported-and-analy
Merit Medical Systems (NASDAQ:MMSI) shares fell 7.6% despite reporting Q3 revenues of US$416m, which were in line with forecasts, and statutory EPS of US$0.70, beating expectations by 3.9%. Following these results, analysts have increased their earnings per share estimates for 2027 and raised the consensus price target by 5.1% to US$107, indicating increased optimism for the company's intrinsic value. The company is projected to grow revenues at a similar rate to the wider industry, with an 8.1% increase in 2027 to US$1.74 billion and EPS rising 24% to US$3.31.
Advertisement

A Quick Look at Today's Ratings for Merit Medical Systems(MMSI.US), With a Forecast Between $106 to $121

https://www.moomoo.com/news/post/1003017953/a-quick-look-at-today-s-ratings-for-merit-medical
This article provides an overview of recent analyst ratings for Merit Medical Systems (MMSI.US), highlighting that analysts maintain a "Buy" consensus with a price target range of $106 to $121. The analysis covers the recent performance and future outlook of the company based on expert evaluations.

Merit Medical Systems, Inc. Stock 12‑Month Price Target Raised to $107, Implies 15% Upside

https://www.tradingview.com/news/tradingview:f0c300dc03ab5:0-merit-medical-systems-inc-stock-12-month-price-target-raised-to-107-implies-15-upside/
Merit Medical Systems, Inc. (MMSI) has seen its average 12-month price target raised from $100.67 to $107 by analysts, with forecasts ranging from $90 to $123 per share. This updated target suggests a potential upside of approximately 15% based on the Oct. 29 closing price. The consensus rating from 13 analysts remains a "Buy," with 9 buy recommendations and 4 holds.

Merit Medical Systems, Inc. Stock 12‑Month Price Target Raised to $107, Implies 15% Upside

https://www.tradingview.com/news/tradingview:f0c300dc03ab5:0-merit-medical-systems-inc-stock-12-month-price-target-raised-to-106-5-implies-14-upside/
Merit Medical Systems, Inc. (MMSI) has seen its average 12-month price target increased to $107 by analysts, up from $100.67. This new target suggests a potential upside of approximately 15% from its recent closing price. The consensus analyst rating for MMSI remains a "Buy."

Needham raises Merit Medical stock price target on strong results

https://www.investing.com/news/analyst-ratings/needham-raises-merit-medical-stock-price-target-on-strong-results-93CH-4986220
Needham raised its price target for Merit Medical Systems, Inc. (NASDAQ: MMSI) to $106 from $101, maintaining a Buy rating after the company's strong third-quarter 2026 revenue and earnings per share exceeded estimates. Management subsequently raised its full-year 2026 guidance. The stock, currently trading at $93.39, is considered undervalued by InvestingPro's Fair Value analysis, despite being near its 52-week high.

These Analysts Boost Their Forecasts On Merit Medical Systems After Strong Q3 Results

https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62731865/these-analysts-boost-their-forecasts-on-merit-medical-systems-after-strong-q3-results
Merit Medical Systems (NASDAQ: MMSI) reported strong third-quarter results, surpassing analyst estimates for both earnings and sales. Following this upbeat performance, the company raised its FY2026 adjusted EPS guidance and narrowed its sales guidance. Consequently, BTIG and Needham analysts maintained their "Buy" ratings and increased their price targets for MMSI stock.
Advertisement

Merit Medical Systems Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62724635/merit-medical-systems-q3-2026-earnings-call-transcript
Merit Medical Systems reported strong Q3 2026 results with total revenue up 8% year-over-year to $416 million and non-GAAP EPS increasing 22%. The company updated its 2026 guidance, expecting GAAP net revenue growth of 7.9% to 8.4% and a non-GAAP EPS range of $4.33 to $4.37. Merit Medical also announced the acquisition of SoloPACE for approximately $45 million, enhancing its Cardiac Therapies platform with temporary pacing technology for TAVR procedures.

Merit Medical Systems Inc. (MMSI) Tops Q3 EPS by 8c; Offers Guidance

https://www.streetinsider.com/Earnings/Merit+Medical+Systems+Inc.+%28MMSI%29+Tops+Q3+EPS+by+8c%3B+Offers+Guidance/27258710.html
Merit Medical Systems Inc. (MMSI) announced its Q3 earnings, reporting an EPS of $1.12, surpassing analyst estimates by $0.08, and revenue of $416.24 million, beating the consensus. The company also provided its FY2026 guidance, projecting EPS between $4.33-$4.37 and revenue of $1.63-1.64 billion, both in line with or slightly above analyst expectations.

Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates

https://finance.yahoo.com/healthcare/articles/merit-medical-mmsi-q3-earnings-220508374.html
Merit Medical (MMSI) reported Q3 2026 earnings of $1.12 per share, surpassing the Zacks Consensus Estimate of $1.04, and revenues of $416.24 million, exceeding the estimate by 1.43%. The company has consistently beaten EPS and revenue estimates over the last four quarters. Despite outperforming expectations, the stock holds a Zacks Rank #3 (Hold) due to mixed estimate revision trends, suggesting it will perform in line with the market.

Freedom Capital Markets initiates coverage of Merit Medical Systems with Hold rating, $90 price target

https://www.tradingview.com/news/tradingview:b58c1be80af75:0-freedom-capital-markets-initiates-coverage-of-merit-medical-systems-with-hold-rating-90-price-target/
Freedom Capital Markets has initiated coverage on Merit Medical Systems (MMSI) with a Hold rating and a $90 price target, implying a 3.8% downside from its recent closing price. The analyst note highlights the company's strong market growth potential, particularly in its Therapeutic segment with projected robust annual growth rates, and its successful diversification strategy that allows it to outpace market growth. These factors are expected to mitigate risks and support sustained earnings, even with a leadership transition.

Merit Medical Price Target Announced at $90.00/Share by Freedom Capital Markets

https://www.moomoo.com/news/post/1002541203/merit-medical-price-target-announced-at-90-00-share-by
Freedom Capital Markets has set a price target of $90.00 per share for Merit Medical (MMSI). The article also briefly mentions Unity Software's fourth-quarter financial results, noting a 35% year-over-year revenue increase to $609 million, surpassing estimates, alongside a quarterly loss of 66 cents per share.
Advertisement

Merit Medical Systems (MMSI) reports earnings tomorrow: what to expect

https://markets.financialcontent.com/stocks/article/stockstory-2026-10-28-merit-medical-systems-mmsi-reports-earnings-tomorrow-what-to-expect
Merit Medical Systems (MMSI) is scheduled to report earnings, with analysts expecting a 6.8% year-on-year revenue growth. The company has a history of surpassing Wall Street's expectations and investors are showing positive sentiment in the healthcare equipment and supplies segment. Its stock is up 7.5% over the last month, heading into earnings with an average analyst price target of $101.64.

Merit Medical Systems stock hits 52-week high at 94.79 USD

https://au.investing.com/news/stock-market-news/merit-medical-systems-stock-hits-52week-high-at-9479-usd-93CH-4715374
Merit Medical Systems Inc. (MMSI) stock reached a new 52-week high of $94.79, reflecting a 58% increase from its 52-week low and a 36% surge in the past six months. This surge follows strong second-quarter results, with revenue of $418.8 million and adjusted EPS of $1.19, both exceeding analyst expectations. Analyst firms like Canaccord and Needham have raised their price targets and maintained "Buy" ratings, signaling positive sentiment for the company's future performance.

Merit Medical Systems stock hits 52-week high at 94.79 USD

https://www.investing.com/news/company-news/merit-medical-systems-stock-hits-52week-high-at-9479-usd-93CH-4973281
Merit Medical Systems Inc. (MMSI) stock recently achieved a 52-week high of $94.79, reflecting a 58% increase from its 52-week low and a 36% surge in the past six months. Despite the rally, InvestingPro analysis suggests the stock is still undervalued, with positive analyst earnings revisions. This follows strong Q2 results, where revenue and adjusted EPS surpassed estimates, leading to raised full-year outlooks and increased price targets from several analyst firms.

Merit Medical Systems, Inc. Estimates – NASDAQ:MMSI

https://www.tradingview.com/symbols/NASDAQ-MMSI/financials-estimates/
This article provides access to financial actuals and analyst estimates for Merit Medical Systems, Inc. (NASDAQ: MMSI) on TradingView. Users can explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform also allows visualization of financial trends over time.

Merit Medical Systems, Inc. Estimates – SWB:MM3

https://www.tradingview.com/symbols/SWB-MM3/financials-estimates/
This article provides an overview of Merit Medical Systems, Inc. (SWB:MM3) financial data and analyst estimates available on TradingView. It highlights sections for income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The platform also offers tools for visualizing financial trends over time.
Advertisement

Merit Medical Systems, Inc. (MMSI) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/MMSI/latest-news/
This article provides a comprehensive overview of Merit Medical Systems, Inc. (MMSI) stock, including its current price, recent news, and historical performance data. It highlights the company's stock activity and lists related news articles from various financial sources. The performance overview compares MMSI's trailing total returns against the S&P 500 benchmark for various periods.

Medical Devices & Supplies - Cardiology, Neurology, Vascular Q2 Earnings: Merit Medical Systems (NASDAQ:MMSI) Simply the Best

https://www.theglobeandmail.com/investing/markets/stocks/MMSI-Q/pressreleases/7851455/medical-devices-supplies-cardiology-neurology-vascular-q2-earnings-merit-medical-systems-nasdaqmmsi-simply-the-best/
Merit Medical Systems (NASDAQ:MMSI) delivered an exceptional Q2, exceeding revenue and EPS guidance, leading to a 4.5% stock increase. While the medical device sector faces R&D costs and regulatory hurdles, it benefits from an aging population and technological advancements. ICU Medical also surpassed expectations, but its stock declined, while Penumbra and Artivion showed mixed results despite revenue growth.

Medical Devices & Supplies - Cardiology, Neurology, Vascular Q2 Earnings: Merit Medical Systems (NASDAQ:MMSI) Simply the Best

https://www.tradingview.com/news/stockstory:9686c28b6094b:0-medical-devices-supplies-cardiology-neurology-vascular-q2-earnings-merit-medical-systems-nasdaq-mmsi-simply-the-best/
The article reviews Q2 earnings for companies in the medical devices & supplies sector, focusing on cardiology, neurology, and vascular care. Merit Medical Systems (MMSI) is highlighted as a top performer with strong revenue growth and a significant beat of analyst estimates, leading to a stock increase. Other companies like ICU Medical (ICUI), Penumbra (PEN), and Artivion (AORT) also had their Q2 results analyzed, showing mixed performances against expectations and varying stock reactions.

Price-Driven Insight from (MMSI) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/35/Price-Driven_Insight_from_MMSI_for_Rule-Based_Strategy_101326041402_1791879242.html
This article provides a price-driven analysis for Merit Medical Systems Inc. (MMSI) using AI models to generate trading strategies. It highlights a near-term strong sentiment but neutral mid and long-term outlook, noting no clear price positioning signal or

Merit Medical Systems (MMSI) Stock Looks Cheap Based On Cash Flow

https://uk.finance.yahoo.com/news/merit-medical-systems-mmsi-stock-051357528.html
Merit Medical Systems (MMSI) has seen a 34.9% share price gain over three years, leading to questions about whether its current US$87.21 price is justified by its expected cash flows. A Discounted Cash Flow (DCF) analysis suggests the company's intrinsic value is currently above its trading price, based on consistent free cash flow generation from recurring demand for its medical devices. While bull and bear narratives exist regarding the company's valuation, Simply Wall St advises considering additional risk factors before finalizing any investment decision.
Advertisement

Cancer Stocks to Consider as Oncology Innovation Accelerates

https://sg.finance.yahoo.com/news/cancer-stocks-consider-oncology-innovation-140300341.html
The global oncology market is experiencing rapid growth due to increasing cancer incidence and medical advancements, making it a significant long-term opportunity for the healthcare industry. Companies like Pfizer, Merit Medical Systems, and Abbott Laboratories are highlighted as potential investment opportunities, with their extensive portfolios and pipelines in cancer treatments and diagnostics. The article emphasizes the transformative impact of immunotherapies, targeted medicines, and personalized vaccines in cancer care.

Merit Medical Systems, Inc. (MMSI) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4142_QuantitativeReport_1791331200000
Argus has lowered its target price for Merit Medical Systems, Inc. (MMSI) to $93.00, citing the company's role as a medical equipment manufacturer for interventional cardiology, radiology, and endoscopy. The report provides a summary of the company and suggests upgrading to premium research for more detailed insights.

Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026

https://finance.yahoo.com/healthcare/articles/merit-medical-systems-announce-third-203000691.html
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for the quarter ended September 30, 2026, after the stock market closes on Thursday, October 29, 2026. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern time. Interested parties can pre-register for the call and access a live webcast and slide deck via links provided on Merit's website.

Merit Medical Systems Sets Oct. 29 Q3 Results Date | MMSI Stock News

https://www.stocktitan.net/news/MMSI/merit-medical-systems-to-announce-third-quarter-2026-results-on-gzu2mbd3g5q8.html
Merit Medical Systems (MMSI) announced it will release its third-quarter 2026 financial results after the stock market closes on October 29, 2026. The company plans to hold an investor conference call on the same day at 4:30 p.m. Eastern Time, with a live webcast and slide deck available.

Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026

https://www.marketscreener.com/news/merit-medical-systems-to-announce-third-quarter-2026-results-on-october-29-2026-ce785dd9dc8df624
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for the third quarter of 2026 on Thursday, October 29, 2026, after the stock market closes. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern Time to discuss the results. Merit Medical, founded in 1987, specializes in developing, manufacturing, and distributing proprietary medical devices for various interventional, diagnostic, and therapeutic procedures.
Advertisement

Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

https://es.tradingview.com/news/zacks:5488a424f094b:0-here-s-why-you-should-add-merit-medical-stock-to-your-portfolio-now/
Merit Medical Systems, Inc. (MMSI) is recommended as a stock to add to portfolios due to its strong product portfolio, global expansion, and strategic acquisitions, despite recent share price declines. The company projects significant growth in the coming years, driven by new product launches like the Resilience Through-the-Scope Esophageal Stent and SCOUT MD, and the potential of its WRAPSODY Cell-Impermeable Endoprosthesis. Key challenges include tariffs, cost pressures, and issues with reimbursement and pricing, particularly in international markets.

Barrington Maintains Merit Medical Systems(MMSI.US) With Buy Rating, Maintains Target Price $114

https://www.moomoo.com/news/post/1000517840/barrington-maintains-merit-medical-systems-mmsius-with-buy-rating-maintains
Barrington has reiterated its Buy rating on Merit Medical Systems (MMSI.US) and maintained its target price at $114. This indicates continued confidence from Barrington in the company's financial performance and future prospects.

Needham Maintains Merit Medical Systems(MMSI.US) With Buy Rating, Maintains Target Price $101

https://www.moomoo.com/news/post/1000372639/needham-maintains-merit-medical-systems-mmsius-with-buy-rating-maintains
Needham has reiterated its Buy rating for Merit Medical Systems (MMSI.US) and maintained its price target of $101. This indicates continued confidence from the analyst firm in the company's stock performance.

Merit Medical Systems, Inc. (MMSI) Stock Analysis: 18.84% Potential Upside Beckons Investors

https://www.directorstalkinterviews.com/merit-medical-systems-inc-mmsi-stock-analysis-18-84-potential-upside-beckons-investors/4121263268
Merit Medical Systems, Inc. (MMSI), a healthcare sector player with a $5.1 billion market cap, shows strong operational performance with 9.50% revenue growth and an EPS of 2.43. Analysts are largely positive, with a consensus target price of $101.45, suggesting an 18.84% upside. The company's focus on reinvesting earnings for growth, coupled with its global presence and diversified product portfolio, makes it an attractive opportunity for growth-oriented investors.

MMSI PE Ratio & Valuation, Is MMSI Overvalued

https://intellectia.ai/en/stock/MMSI/valuation
Merit Medical Systems Inc (MMSI) is currently considered undervalued, with a forward PE ratio of 18.69 compared to its five-year average of 24.34. Its fair price is estimated to be between $96.51 and $121.84, making it undervalued by 11.54% relative to its current price of $85.37. While its P/S ratio of 2.94 is slightly above the industry average of 2.90, this premium may be unsustainable given its 9.51% revenue growth.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement